Search clinical trials for: Debio 4126

Total 142 results

Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Debiopharm International SA
Caris Life Sciences; Optimal Research (Just In Time sites)

Terminated

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Solid Tumor

United States, Spain, Austria, Czechia, Denmark, Russian Federation, United Kingdom, Greece, Norway, Korea, Republic of, France, Taiwan, Netherlands, Bulgaria, Finland, Ukraine, Australia, Brazil, Croatia, Philippines, Poland, Rom... and more
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Healthy

United Kingdom
Debiopharm International SA

Recruiting

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Switzerland
Debiopharm International SA

Completed

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma | Cancer | Solid Tumors | Malignancy

United States
Sarepta Therapeutics, Inc.

Completed

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

Neoplasms

United States
Debiopharm International SA

Completed

Study of Debio 1450 for Bacterial Skin Infections

Bacterial Infections

United States
Debiopharm International SA

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Bacterial Infections

United States
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Debiopharm International SA

Completed

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Healthy

United Kingdom
Debiopharm International SA

Completed

A Single Dose Study of Debio 1450 in Healthy Subjects

Bacterial Infections

United States
Clavis Pharma

Completed

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Advanced Adenocarcinoma of Pancreas

Norway, Belgium
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
LG Life Sciences

Unknown

Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients

ST-segment Elevation Myocardial Infarction

Korea, Republic of
LG Life Sciences

Completed

Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients

ST-segment Elevation Myocardial Infarction

Korea, Republic of
Debiopharm International SA

Completed

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Bone Diseases, Infectious

United States
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Invicro

Completed

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Parkinson Disease | Alzheimer Disease | Healthy Volunteers

United States
Tau Pnu Medical Co., Ltd.

Completed

The Effect of "Cerclage Pacing" for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT) (Cerclage-CRT)

Heart Failure | LBBB Complete

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Debiopharm International SA

Recruiting

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands, Spain
Debiopharm International SA

Terminated

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Solid Tumors

France
Vyant Bio

Not yet recruiting

Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients

Rett Syndrome
LG Chem

Completed

A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.

Healthy

Korea, Republic of
Sarepta Therapeutics, Inc.

Terminated

Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

Cardiovascular Disease | Coronary Artery Bypass

Ukraine
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
University Hospital, Tours

Completed

Study of Hemodynamic Conditions Measured During Hepatectomy (DEBIFOIE)

Liver Dysfunction | Circulatory; Change

France
MedImmune LLC

Completed

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
LG Life Sciences

Completed

Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Healthy

Korea, Republic of
Myrexis Inc.

Completed

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

HIV-1 Infection

United States
Abbott

Completed

A Safety and Tolerability Study of ABT-126 in Elderly

Alzheimer's Disease

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital

Active, not recruiting

Cash Benefits and Reproductive/Perinatal Health

Pregnancy Related | Miscarriage | Maternal Care Patterns

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital; Cambridge Health Alliance

Active, not recruiting

Effect of Cash Benefits on Health Care Utilization

Health Care Utilization

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Romania, Spain, Switzerland, Netherlands, Poland, Por...
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
Repros Therapeutics Inc.

Terminated

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Endometriosis

United States
Charite University, Berlin, Germany

Unknown

WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Charite University, Berlin, Germany

Unknown

WT1 Peptid Vaccination in Carcinomas

WT1 Expressing Carcinoma

Germany
AbbVie (prior sponsor, Abbott)

Completed

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Head and Neck Cancer

Taiwan, United States, Korea, Republic of, Spain, Belgium

3

Subscribe